Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Bioorg Med Chem Lett ; 29(8): 995-1000, 2019 04 15.
Artículo en Inglés | MEDLINE | ID: mdl-30792038

RESUMEN

Oxadiazole replacement of an amide linkage in an RARα agonist template 1, followed by lead optimisation, has produced a highly potent and selective RARß agonist 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (10) with good oral bioavailability in the rat and dog. This molecule increases neurite outgrowth in vitro and induces sensory axon regrowth in vivo in a rodent model of avulsion and crush injury, and thus has the potential for the treatment of nerve injury.


Asunto(s)
Oxadiazoles/química , Receptores de Ácido Retinoico/agonistas , Administración Oral , Animales , Perros , Evaluación Preclínica de Medicamentos , Semivida , Locomoción/efectos de los fármacos , Células de Riñón Canino Madin Darby , Proyección Neuronal/efectos de los fármacos , Traumatismos del Nervio Óptico/tratamiento farmacológico , Oxadiazoles/farmacocinética , Oxadiazoles/farmacología , Ratas , Receptores de Ácido Retinoico/metabolismo , Relación Estructura-Actividad
2.
J Biol Chem ; 281(42): 31279-89, 2006 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-16899457

RESUMEN

Gamma-secretase is one of the critical enzymes required for the generation of amyloid-beta peptides from the beta-amyloid precursor protein. Because amyloid-beta peptides are generally accepted to play a key role in Alzheimer disease, gamma-secretase inhibition holds the promise for a disease-modifying therapy for this neurodegenerative condition. Although recent progress has enhanced the understanding of the biology and composition of the gamma-secretase enzyme complex, less information is available on the actual interaction of various inhibitor classes with the enzyme. Here we show that the two principal classes of inhibitor described in the scientific and patent literature, aspartyl protease transition state analogue and small molecule non-transition state inhibitors, display fundamental differences in the way they interact with the enzyme. Taking advantage of a gamma-secretase enzyme overexpressing cellular system and different radiolabeled gamma-secretase inhibitors, we observed that the maximal binding of non-transition state gamma-secretase inhibitors accounts only for half the number of catalytic sites of the recombinant enzyme complex. This characteristic stoichiometry can be best accommodated with a model whereby the non-transition state inhibitors bind to a unique site at the interface of a dimeric enzyme. Subsequent competition studies confirm that this site appears to be targeted by the main classes of small molecule gamma-secretase inhibitor. In contrast, the non-steroidal anti-inflammatory drug gamma-secretase modulator sulindac sulfide displayed noncompetitive antagonism for all types of inhibitor. This finding suggests that non-steroidal anti-inflammatory drug-type gamma-secretase modulators target an alternative site on the enzyme, thereby changing the conformation of the binding sites for gamma-secretase inhibitors.


Asunto(s)
Secretasas de la Proteína Precursora del Amiloide/química , Secretasas de la Proteína Precursora del Amiloide/metabolismo , Antiinflamatorios no Esteroideos/farmacología , Unión Competitiva , Bioquímica/métodos , Dominio Catalítico , Línea Celular , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Inhibidores Enzimáticos/farmacología , Humanos , Cinética , Ligandos , Modelos Químicos , Unión Proteica , Sulindac/análogos & derivados , Sulindac/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA